New pill shows promise for shedding pounds in obesity trial

NCT ID NCT06703021

Completed Disease control Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called aleniglipron (GSBR-1290) to help people with obesity or overweight lose weight. About 85 adults took either the drug or a placebo for 44 weeks, along with diet and exercise. The main goal was to check safety and side effects, while also measuring how much weight people lost.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC WEIGHT MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC WEIGHT MANAGEMENT OBESITY OVERWEIGHT

Contacts and locations

Locations

ACCESS II Research Site

Glendale, California, 91206, United States
ACCESS II Research Site

Montclair, California, 91763, United States
ACCESS II Research Site

Valparaiso, Indiana, 46383, United States
ACCESS II Research Site

West Des Moines, Iowa, 50265, United States
ACCESS II Research Site

Medford, Oregon, 97504, United States
ACCESS II Research Site

East Greenwich, Rhode Island, 02818, United States
ACCESS II Research Site

North Charleston, South Carolina, 29405, United States
ACCESS II Research Site

Dallas, Texas, 75042, United States
ACCESS II Research Site

San Antonio, Texas, 78240, United States
ACCESS II Research Site

West Jordan, Utah, 84088, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.